Volume 19, Issue 4, Pages 562-578 (April 2018) 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial  Timothy J Iveson, MD, Prof Rachel S Kerr, FRCP, Mark P Saunders, FRCR, Prof Jim Cassidy, MD, Niels Henrik Hollander, MD, Josep Tabernero, MD, Andrew Haydon, MBBS, Prof Bengt Glimelius, MD, Andrea Harkin, BA, Karen Allan, BSc, John McQueen, BSc, Claire Scudder, MSc, Kathleen Anne Boyd, PhD, Prof Andrew Briggs, DPhil, Ashita Waterston, PhD, Louise Medley, FRCP, Charles Wilson, FRCR, Richard Ellis, FRCR, Sharadah Essapen, MD, Amandeep S Dhadda, MBChB, Mark Harrison, PhD, Stephen Falk, MD, Sherif Raouf, FRCR, Charlotte Rees, FRCP, Rene K Olesen, MD, David Propper, MD, Prof John Bridgewater, MD, Ashraf Azzabi, MD, David Farrugia, PhD, Andrew Webb, FRCP, Prof David Cunningham, MD, Tamas Hickish, MD, Andrew Weaver, MD, Simon Gollins, DPhil, Harpreet S Wasan, FRCP, James Paul, BSc [Hons]  The Lancet Oncology  Volume 19, Issue 4, Pages 562-578 (April 2018) DOI: 10.1016/S1470-2045(18)30093-7 Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions

Figure 1 Trial profile ITT=intention to treat. CTCAE=Common Terminology Criteria for Adverse Events. *Based on retrospective review. †Patients could have more than one reason. The Lancet Oncology 2018 19, 562-578DOI: (10.1016/S1470-2045(18)30093-7) Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions

Figure 2 Disease-free survival (A) and overall survival (B) by study group HR=hazard ratio. The Lancet Oncology 2018 19, 562-578DOI: (10.1016/S1470-2045(18)30093-7) Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions

Figure 3 Disease-free survival and heterogeneity in subgroups by minimisation variables Categories are listed as recorded at randomisation; ten patients in the 3 month group and 15 patients in the 6 month group could not be allocated to high risk stage II or stage III based on T/N data recorded at randomisation. *These estimates differ slightly because the underlying multivariable Cox model on which they are based includes parameters for other minimisation variables, as well as those factors relating to stage; the increased flexibility in the expanded stage model allows the influence of these parameters on the high risk stage II estimates to modify. The Lancet Oncology 2018 19, 562-578DOI: (10.1016/S1470-2045(18)30093-7) Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions

Figure 4 Disease-free survival by study group and selected adjuvant regimen HR=hazard ratio. The Lancet Oncology 2018 19, 562-578DOI: (10.1016/S1470-2045(18)30093-7) Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions

Figure 5 Treatment delivery by selected adjuvant regimen Box and whisker plots indicate median and IQR (boxes) and range (whiskers). Dots represent outliers. The Lancet Oncology 2018 19, 562-578DOI: (10.1016/S1470-2045(18)30093-7) Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions

Figure 6 Disease-free survival by study group and stage III risk group HR=hazard ratio. The Lancet Oncology 2018 19, 562-578DOI: (10.1016/S1470-2045(18)30093-7) Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions

Figure 7 Peripheral neuropathy by study group Patients reported peripheral neuropathy with the GOG Ntx4 questionnaire. Although results were available beyond year 6, they have been omitted because of small numbers and resultant wide confidence intervals. Error bars show 95% CIs. *The low completion rates at these timepoints reflect the fact that, initially, neurotoxicity data were only collected up to 12 months and there was a delay before an amendment extended the collection to the whole study period. †Low return rate because patients were assessed at the start of last cycle rather than 6 months (which corresponds to end of cycle). The Lancet Oncology 2018 19, 562-578DOI: (10.1016/S1470-2045(18)30093-7) Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions